國家衛生研究院 NHRI:Item 3990099045/3749
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 924756      線上人數 : 953
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    主頁登入上傳說明關於NHRI管理 到手機版
    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/3749


    題名: Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity
    作者: Chiang, YK;Kuo, CC;Wu, YS;Chen, CT;Coumar, MS;Wu, JS;Hsieh, HP;Chang, CY;Jseng, HY;Wu, MH;Leou, JS;Song, JS;Chang, JY;Lyu, PC;Chao, YS;Wu, SY
    貢獻者: Division of Biotechnology and Pharmaceutical Research;National Institute of Cancer Research
    摘要: A pharmacophore model, Hypo1, was built on the basis of 21 training-set indole compounds with varying levels of antiproliferative activity. Hypo1 possessed important chemical features required for the inhibitors and demonstrated good predictive ability for biological activity, with high correlation coefficients of 0.96 and 0.89 for the training-set and test-set compounds, respectively. Further utilization of the Hypo1 pharmacophore model to screen chemical database in silico led to the identification of four compounds with antiproliferative activity. Among these four compounds, 43 showed potent antiproliferative activity against various cancer cell lines with the strongest inhibition on the proliferation of KB cells (IC50 = 187 nM). Further biological characterization revealed that 43 effectively inhibited tubulin polymerization and significantly induced cell cycle arrest in G2-M phase. In addition, 43 also showed the in vivo-like anticancer effects. To our knowledge, 43 is the most potent antiproliferative compound with antitubulin activity discovered by computer-aided drug design. The chemical novelty of 43 and its anticancer activities make this compound worthy of further lead optimization.
    日期: 2009-07-23
    關聯: Journal of Medicinal Chemistry. 2009 Jul 23;52(14):4221-4233.
    Link to: http://dx.doi.org/10.1021/jm801649y
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0022-2623&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000268139900019
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=67650720900
    顯示於類別:[伍素瑩] 期刊論文
    [趙宇生(2002-2013)] 期刊論文
    [謝興邦] 期刊論文
    [陳炯東] 期刊論文
    [張俊彥] 期刊論文
    [郭靜娟] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    SCP67650720900.pdf4563KbAdobe PDF905檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋